BUZZ-Leerink believes that as Anthropic enters the field of biology, life science tools will benefit.

September 24 - ** Leerink Partners stated that Anthropic is increasingly focusing on the field of biology, which may drive demand for laboratory automation, experiments, and large-scale data needed to validate AI predictions.

** The brokerage believes biotechnology company Twist Bioscience (TWST.O) is “the most significant beneficiary,” citing growing market demand for synthetic DNA used to transform AI-designed proteins into testable molecules.

** According to the report, Anthropic is funding laboratory tests on 5,000 protein design projects using Twist’s synthetic DNA, highlighting the company’s role in AI-driven drug discovery.

** Leerink stated that Anthropic’s Claude can analyze complex laboratory data in 19 to 23 minutes, which may allow researchers to advance follow-up experiments more quickly.

** The brokerage noted that early protein design results are encouraging but more data and laboratory testing are still needed to develop designs suitable for pharmaceuticals.

(For the convenience of non-English speakers, Reuters has automated the translation of its reports into several other languages. Since automated translation may contain errors or lack the required context, Reuters does not guarantee the accuracy of the automated translation text and provides it solely for the convenience of readers. Reuters assumes no responsibility for any damage or loss caused by the use of the automated translation function.)